Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
WHO Reporting System for Lung Cytopathology VOL. 1
IAC-IARC-WHO Cytopathology Reporting Systems, 1st Edition
aa.vv
Editore
IARC
Anno
2022
Pagine
210
ISBN
9789283245162
105,00 €
The WHO Reporting System for Lung Cytopathology is Volume 1 of this new series of reporting systems for cytopathology, which is a joint project of the International Academy of Cytology (IAC) and the International Agency for Research on Cancer (IARC), a specialized agency of the World Health Organization (WHO). The series includes a unique synthesis of the published evidence and the practice of cytopathology, and it is linked to the WHO Classification of Tumours series, now in its 5th edition.
Cytopathologists look at tumours slightly differently than other specialists do, and there is a need for specialized reporting systems based on the key diagnostic cytopathological features of tumours, presented in standardized reports, within a hierarchical system of diagnostic categories. These categories must also be linked to diagnostic management recommendations to improve communication with clinicians and support patient care. And it is essential that these reporting systems be truly international, to serve the needs of patients worldwide in many differently medically resourced settings.
What are the key features of this first edition of the series?
These volumes are an essential tool for standardizing diagnostic cytopathology practice worldwide and will serve as a vehicle for the translation of cytopathology research into practice. The key diagnostic cytopathological features are listed for each tumour type under a defined set of diagnostic categories and described in precise, uniform language. These diagnostic criteria represent the first international consensus and are underpinned by evidence that has been evaluated and debated by experts in the field. Each lesion-specific section includes a dedicated subsection discussing the differential diagnosis of the cytopathological features that can be used throughout the world, including in low-resource settings, followed by a subsection describing the current best-practice application of ancillary testing (including next-generation sequencing) on cytopathology material.
This volume
- Prepared by about 60 authors and editors
- Contributors from around the world, reflecting an international expertise
- More than 300 high-quality images
- More than 1000 references
List of abbreviations viii Foreword ix 1 Introduction to the WHO Reporting System for Lung Cytopathology 1 Background 2 The role of lung cytopathology 6 Diagnostic categories and report structure 8 Risk of malignancy and management recommendations 11 2 Lung cytopathology techniques 13 Sampling methods FNAB techniques and specimen management 14 Bronchial wash and bronchial brush techniques and specimen management 16 Bronchoalveolar lavage techniques and specimen management 18 Sputum sampling techniques and specimen management 20 Rapid onsite evaluation 22 Cell preparation methods 24 Ancillary testing Introduction: The role of ancillary testing 26 Immunocytochemistry 27 In situ hybridization 31 Molecular testing 34 3 Diagnostic category: Insufficient/Inadequate/Non-diagnostic 39 Introduction 40 Definition 40 Discussion and background 41 Risk of malignancy and management recommendations 44 Sample reports 45 4 Diagnostic category: Benign 47 Introduction 48 Definition 48 Discussion and background 49 Risk of malignancy and management recommendations 50 Inflammatory processes Acute inflammation and suppuration 51 Histiocytic, lymphocytic, and eosinophilic inflammatory patterns 53 Granulomatous disorders 58 Inflammatory and reactive changes in glandular cells and squamous cells 61 Benign neoplastic lesions Pulmonary hamartoma 66 Sclerosing pneumocytoma 68 Solitary tracheobronchial papilloma 71 Salivary gland neoplasms 72 PEComa 73 Spindle cell tumours 75 Meningiomas 78 Granular cell tumour 79 Ectopic thyroid and parathyroid tissues 81 Sample reports 83 5 Diagnostic category: Atypical 85 Introduction 86 Definition 86 Discussion and background 87 Risk of malignancy and management recommendations 90 Sample reports 91 6 Diagnostic category: Suspicious for malignancy 95 Introduction 96 Definition 96 Discussion and background 97 Risk of malignancy and management recommendations 99 Sample reports 100 7 Diagnostic category: Malignant 103 Introduction 104 Definition 104 Discussion and background 105 Risk of malignancy and management recommendations 108 Specific malignant lesions Non-small cell carcinomas Adenocarcinoma of the lung 109 Squamous cell carcinoma 114 Non-small cell carcinoma NOS 118 Other specific carcinomas Salivary gland–type carcinomas 120 Adenosquamous carcinoma 123 Pleomorphic carcinoma 126 Pulmonary blastoma 128 Carcinosarcoma 129 NUT carcinoma 131 Thoracic SMARCA4-deficient undifferentiated tumour 133 Neuroendocrine neoplasms Neuroendocrine tumours Carcinoid/neuroendocrine tumours of the lung 135 Neuroendocrine carcinomas Small cell lung carcinoma 139 Large cell neuroendocrine carcinoma 142 Lymphoproliferative diseases Lymphomas 144 Pulmonary Langerhans cell histiocytosis 147 Erdheim–Chester disease 148 Other malignancies Spindle cell tumours 150 Paraganglioma 154 Diffuse pleural mesothelioma 156 Primary germ cell tumours of the mediastinum 163 Primary angiosarcoma of the lung 168 Pulmonary and thoracic metastases 170 Sample reports 173 8 Management recommendations for each diagnostic category 177 Introduction 178 Insufficient/Inadequate/Non-diagnostic 179 Benign 181 Atypical 182 Suspicious for malignancy 183 Malignant 184 Contributors 185 Declaration of interests 187 Sources 189 References 193 Subject index 20
